Tyrosine kinase inhibition of the epidermal growth factor receptor (EGFR) is thestandard in the first line treatment of patients with advancednon-small–cell lung cancer (NSCLC) harbouring EGFR activating mutations.Here we aim to discern efficacy and toxicity measures through a meta-analysis ofpublished studies that could aid treatment selection. This evidence concerns the gene EGFR and non-small cell lung carcinoma.